STOCK TITAN

Adaptive Biotechnologies Corporation - $ADPT STOCK NEWS

Welcome to our dedicated page for Adaptive Biotechnologies Corporation news (Ticker: $ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies Corporation stock.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is a commercial-stage biotechnology company dedicated to leveraging the intricate biology of the adaptive immune system to innovate in the diagnosis and treatment of diseases. The company's proprietary immune medicine platform combines high-throughput sequencing with cutting-edge computational infrastructure to offer detailed analyses of T- and B-cell repertoires, critical elements in the body's immune response. Adaptive focuses on two primary business areas: Minimal Residual Disease (MRD) and Immune Medicine.

One of Adaptive's flagship products is clonoSEQ®, a highly sensitive and standardized test authorized by the FDA for detecting minimal residual disease (MRD) in patients with multiple myeloma (MM), B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL). The clonoSEQ test is also available as a CLIA-validated laboratory developed test (LDT) for other lymphoid cancers, such as diffuse large B-cell lymphoma (DLBCL). The MRD status measured by clonoSEQ serves as a powerful predictor of patient outcomes, aiding in personalized treatment and monitoring strategies.

Adaptive Biotechnologies has formed strategic partnerships with leading biopharmaceutical companies. For instance, it collaborates with Genentech on T-cell receptor (TCR) based therapeutic products, providing a neoantigen-specific T-cell receptor identified using Adaptive's TCR discovery platform. The company also signed a multi-year collaboration with BeiGene to use clonoSEQ technology in developing novel therapies for lymphoid malignancies.

In terms of financial achievements, for the year ended December 31, 2023, Adaptive reported a total revenue of $170.3 million, with the MRD revenue contributing significantly to this growth. The company achieved substantial progress in clonoSEQ test volume and introduced strategic updates to maximize the value of its MRD and Immune Medicine businesses.

Adaptive Biotechnologies operates from biotech hubs in Seattle, Washington, and South San Francisco, California. Their team of world-class scientists and open, collaborative culture drive continuous innovation. The company's clinical diagnostics and pipeline developments aim to transform the clinical landscape, offering new hope for treating cancers, autoimmune disorders, and infectious diseases.

Recently, Adaptive Biotechnologies announced significant progress and strategic decisions to enhance its business operations. They integrated clonoSEQ into Epic’s specialty diagnostics suite, easing MRD monitoring accessibility for healthcare providers. The company continues to focus on driving operational efficiencies, as reflected by a decrease in operating expenses while maintaining sustainable growth.

Adaptive Biotechnologies remains committed to leveraging the adaptive immune system's potent capabilities to develop and commercialize immune-driven clinical products tailored to individual patient needs. With a robust cash position, Adaptive aims for profitability in its MRD business while making targeted investments in Immune Medicine.

Rhea-AI Summary
Adaptive Biotechnologies Corporation (ADPT) presents new data on the expanding use of its clonoSEQ test in assessing minimal residual disease (MRD) in blood cancer patient care and clinical trials at the 65th Annual Meeting of the American Society of Hematology (ASH). The data shows that MRD assessed from blood in multiple myeloma may be an indicator of early response. The clonoSEQ test is the only FDA-cleared test for MRD assessment in lymphoid malignancies and is highly accurate, sensitive, and standardized compared to other technologies used for disease burden assessment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Adaptive Biotechnologies Corporation (ADPT) will present data from over 30 abstracts at the 65th Annual Meeting of the American Society of Hematology, showcasing the clinical and research utility of clonoSEQ in assessing minimal residual disease in blood cancer patients. The PR emphasizes clonoSEQ's FDA clearance and its role in guiding personalized care and shaping the future of blood cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
conferences
-
Rhea-AI Summary
ADPT: Adaptive Biotechnologies Reports Q3 2023 Financial Results, Revenue Down 21% YoY, Strategic Review Underway, MRD Revenue Up 24%, Immune Medicine Revenue Down 52%
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.18%
Tags
Rhea-AI Summary
Adaptive Biotechnologies Corporation announces a multi-year collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ® assay technology across the company’s pipeline of treatments for patients with lymphoid malignancies. This collaboration aims to support the clinical development and potential regulatory approval of investigational therapies in lymphoid malignancies by integrating MRD status into clinical studies to evaluate and advance novel therapeutics more quickly and efficiently.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
-
Rhea-AI Summary
Adaptive Biotechnologies Corporation will report financial results for Q3 2023 on November 9, 2023. The company aims to translate the genetics of the adaptive immune system into clinical products. The conference call will be webcasted and available for replay on the company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
conferences earnings
-
Rhea-AI Summary
Adaptive Biotechnologies integrates clonoSEQ test into Epic's diagnostics suite, providing easier access to MRD monitoring in blood cancers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
Rhea-AI Summary
Adaptive Biotechnologies to participate in Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.44%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
conferences earnings

FAQ

What is Adaptive Biotechnologies Corporation known for?

Adaptive Biotechnologies is known for its proprietary immune medicine platform that analyzes T- and B-cell repertoires to innovate in disease diagnosis and treatment, particularly through its clonoSEQ test for minimal residual disease (MRD).

What is clonoSEQ?

clonoSEQ is an FDA-authorized test for detecting minimal residual disease (MRD) in patients with multiple myeloma (MM), B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL). It is also available as a laboratory-developed test (LDT) for other lymphoid cancers.

Who are some of Adaptive Biotechnologies' key partners?

Adaptive collaborates with leading biopharmaceutical companies like Genentech and BeiGene to develop innovative therapies, particularly focusing on T-cell receptor (TCR) based therapeutic products and MRD assessment.

What were Adaptive Biotechnologies' financial highlights for 2023?

Adaptive reported a total revenue of $170.3 million for the year ended December 31, 2023, with significant contributions from its MRD business. The company also achieved substantial progress in clonoSEQ test volume.

How does Adaptive Biotechnologies contribute to personalized medicine?

Adaptive's immune medicine platform and products like clonoSEQ enable personalized diagnosis, monitoring, and treatment of diseases by leveraging detailed immune system analyses to tailor clinical products to individual patient needs.

What recent strategic decisions has Adaptive Biotechnologies made?

Adaptive has focused on driving operational efficiencies, integrating clonoSEQ into Epic’s diagnostics suite for easier MRD monitoring, and enhancing the independence of its MRD and Immune Medicine businesses to maximize shareholder value.

Where are Adaptive Biotechnologies' main operations located?

Adaptive Biotechnologies operates from biotech hubs in Seattle, Washington, and South San Francisco, California.

What is the company culture at Adaptive Biotechnologies?

Adaptive's culture emphasizes hard work, collaboration, open communication, and innovation, driven by a passionate team committed to making a difference in the world.

What are some key clinical applications of clonoSEQ?

clonoSEQ is used for MRD assessment to predict patient outcomes, evaluate treatment response, and inform clinical decisions in diseases like multiple myeloma, B-ALL, CLL, and other lymphoid cancers.

What are Adaptive Biotechnologies' future goals?

Adaptive aims to continue developing and commercializing immune-driven clinical products tailored to individual patient needs while achieving profitability in its MRD business and advancing key programs in Immune Medicine through targeted investments.

Adaptive Biotechnologies Corporation

Nasdaq:ADPT

ADPT Rankings

ADPT Stock Data

477.47M
81.72M
2.02%
100.66%
8.92%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SEATTLE